Advantages of glucagon-like peptide agonists in the light of prevention of cardiovascular and renal complications
T. Yu. Demidova,
V. V. Titova,
D. V. Skuridina
Abstract:Glucagon-like peptide-1 receptor agonists (arGPP-1) have proven their advantages in persistent reduction of glycemia and HbA1c and achieving targeted control in patients with type 2 diabetes mellitus (DM2) as monotherapy or in combination with other medications. These drugs are also highly effective in reducing body weight for both patients with and without DM2.The research results indicate the potential of arGPP-1 in reducing cardiovascular events, especially in patients with pre-existing atherosclerotic dise… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.